The abstract is read at the publisher; the summary is JClub's.
Circulating thymidine kinase activity predicts survival in SECOMBIT trial patients with BRAF V600-mutated metastatic melanoma, with TKa-low showing 70.7% vs 36.9% overall survival.
- Why it matters: A subset needing initial tumor control with BRAF/MEK-targeted therapy lacks clear biomarkers to guide first- and second-line sequencing.
- What they did: Serum TKa was measured at baseline and during treatment in the randomized phase II SECOMBIT trial (NCT02631447), stratifying patients by median baseline TKa and comparing outcomes across arms A–C.
- The result: TKa-low patients had longer total PFS and OS in arms A and B, while TKa-high patients had improved outcomes with the sandwich strategy; longitudinal data showed early TKa increases on ICI and rising TKa at progression.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.